GALT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Galectin Therapeutics Inc (GALT) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators are mixed, with bearish moving averages and neutral RSI, while the MACD shows slight positive momentum. Options data suggests low put-call ratios, indicating bullish sentiment, but the lack of significant trading trends and weak financial performance, including declining net income and EPS, make it a less compelling choice. Additionally, there are no recent news catalysts or congress trading data to support a buy decision.
The MACD is slightly positive at 0.0595, indicating mild bullish momentum. RSI is neutral at 59.193, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 2.801, R1: 2.95, S1: 2.652, R2: 3.042, S2: 2.56.
Analyst H.C. Wainwright raised the price target from $6 to $11, citing confidence in the company's metabolic dysfunction-associated steatohepatitis program. Options data shows bullish sentiment with a low put-call ratio.
No significant trading trends from hedge funds or insiders. Financial performance is weak, with declining net income (-26.83% YoY) and EPS (-27.78% YoY). No recent news or congress trading data to support a buy.
In Q3 2025, revenue remained at $0 with no growth. Net income dropped to -$8.22M (-26.83% YoY), and EPS declined to -$0.13 (-27.78% YoY). Gross margin stayed at 0%.
H.C. Wainwright analyst maintains a Buy rating and raised the price target from $6 to $11, citing confidence in the company's biomarker data and program.
